A Phase II, Single Arm, Open-Label, Multi-Center, Safety and Tolerability Trial With Nab-paclitaxel (Abraxane) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment For Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and an ECOG Performance Status of 2 (Abound.PS 2).

Trial Profile

A Phase II, Single Arm, Open-Label, Multi-Center, Safety and Tolerability Trial With Nab-paclitaxel (Abraxane) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment For Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and an ECOG Performance Status of 2 (Abound.PS 2).

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms AboundPS2
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 18 Oct 2017 Results determining concordance between patient and physician reported performance status as well as change in performance status with chemotherapy, presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results assessing safety and efficacy of nab-paclitaxel/carboplatin induction followed by nab-paclitaxel monotherapy, presented at the 18th World Conference on Lung Cancer.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top